Cefa-Cilinas Biotics Profile
Key Indicators
- Authorised Capital ₹ 3.50 M
- Paid Up Capital ₹ 3.50 M
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 Cr
- Revenue Growth -51.83%
- Profit Growth -149.36%
- Ebitda -130.71%
- Net Worth -24.67%
- Total Assets 10.14%
About Cefa-Cilinas Biotics
Cefa-Cilinas Biotics Private Limited (CBPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 12 March 2016 (Eight years and 11 months 3 days old ). Its registered office is in Aurangabad, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.50 M and a paid-up capital of Rs 3.50 M.
The company currently has active open charges totaling ₹1.00 Cr.
Dhanraj Rathod and Arjun Rathod serve as directors at the Company.
Company Details
-
Location
Aurangabad, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24296MH2016PTC274279
-
Company No.
274279
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
12 Mar 2016
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Cefa-Cilinas Biotics?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dhanraj Rathod
|
Managing Director | 12-Mar-2016 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Arjun Rathod
|
Director | 07-Feb-2023 | Current |
Financial Performance of Cefa-Cilinas Biotics.
Cefa-Cilinas Biotics Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 51.83% decrease. The company also saw a substantial fall in profitability, with a 149.36% decrease in profit. The company's net worth observed a substantial decline by a decrease of 24.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cefa-Cilinas Biotics?
In 2018, Cefa-Cilinas Biotics had a promoter holding of 50.00% and a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Cefa Cilinas Pharmaceuticals Private LimitedDhanraj Rathod is a mutual person
Charges (Loans)
₹10.00 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 1.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Feb 2023 | State Bank Of India | ₹1.00 Cr | Open |
How Many Employees Work at Cefa-Cilinas Biotics?
Unlock and access historical data on people associated with Cefa-Cilinas Biotics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cefa-Cilinas Biotics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cefa-Cilinas Biotics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
